WRBY Stock Analysis: Warby Parker | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 3.382m USD | 12M Return: 30.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 86.5M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 4.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Warby Parker Inc. (NYSE: WRBY) is a U.S.-based eyewear retailer that sells prescription and non-prescription glasses, sunglasses, contact lenses, and related accessories through a combination of physical stores, e-commerce websites, and mobile apps, primarily serving customers in the United States and Canada. The company operates a direct-to-consumer (DTC) model, which traditionally bypasses third-party retailers to sell branded products straight to end customers.
In addition to its product lineup-which includes blue-light-filtering, polarized, and light-responsive lenses-Warby Parker generates revenue from optical services such as eye exams and vision tests offered through its retail locations. It is classified within the Consumer Discretionary sector under the Other Specialty Retail sub-industry and went public on the NYSE in late September 2021 at a mid-cap market value.
The company was incorporated in 2009 and remains headquartered in New York, New York. Warby Parker competes in the broader eyewear and optical retail market against traditional optometry chains, independent optical shops, and other DTC eyewear brands, differentiating itself through vertically integrated brand ownership and an omnichannel fulfillment approach.
- E-commerce channel growth drives eyeglass and sunglass revenue
- New retail store openings expand physical footprint and capital allocation
- Amazon and insurer competition pressures eyewear pricing and margins
| Net Income: 1.35m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.93 > 1.0 |
| NWC/Revenue: 22.95% < 20% (prev 26.16%; Δ -3.21% < -1%) |
| CFO/TA 0.14 > 3% & CFO 105.9m > Net Income 1.35m |
| Net Debt (-50.6m) to EBITDA (54.0m): -0.94 < 3 |
| Current Ratio: 2.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.6m) vs 12m ago 0.74% < -2% |
| Gross Margin: 53.41% > 18% (prev 54.79%; Δ -1.38% > 0.5%) |
| Asset Turnover: 125.5% > 50% (prev 116.5%; Δ 9.05% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.28 (Total Current Assets 357.7m - Total Current Liabilities 153.3m) / Total Assets 736.4m |
| B: -0.93 (Retained Earnings -682.4m / Total Assets 736.4m) |
| C: 0.00 (EBIT TTM 2.12m / Avg Total Assets 709.6m) |
| D: 1.04 (Book Value of Equity 375.8m / Total Liabilities 360.6m) |
| Altman-Z'' = -0.09 = B |
| DSRI: 1.07 (Receivables 1.76m/1.47m, Revenue 890.6m/795.1m) |
| GMI: 1.03 (GM 54.79% / 53.41%) |
| AQI: 1.37 (AQ_t 0.02 / AQ_t-1 0.01) |
| SGI: 1.12 (Revenue 890.6m / 795.1m) |
| TATA: -0.14 (NI 1.35m - CFO 105.9m) / TA 736.4m) |
| Beneish M = -2.65 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 29.05 with a total of 1,192,178 shares traded. Over the past week, the price has changed by -0.72%, over one month by +16.11%, over three months by +39.53% and over the past year by +30.80%.
Current recommended Stop Loss: 25.50 (which is 12.2% or 2.1 ATR below the current price).
Warby Parker has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy WRBY.
- StrongBuy: 6
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30.2 | 3.8% |
P/E Trailing = 2756.0
P/E Forward = 96.1538
P/S = 3.7976
P/B = 9.5546
Revenue TTM = 890.6m USD
EBIT TTM = 2.12m USD
EBITDA TTM = 54.0m USD
Long Term Debt = 205.8m USD (estimated: total debt 237.6m - short term 31.9m)
Short Term Debt = 31.9m USD (from shortTermDebt, last quarter)
Debt = 237.6m USD (from shortLongTermDebtTotal, last quarter) (leases 237.6m already included)
Net Debt = -50.6m USD (calculated: Debt 237.6m - CCE 288.2m)
Enterprise Value = 3.33b USD (3.38b + Debt 237.6m - CCE 288.2m)
Interest Coverage Ratio = unknown (Ebit TTM 2.12m / Interest Expense TTM 0.0)
EV/FCF = 85.63x (Enterprise Value 3.33b / FCF TTM 38.9m)
FCF Yield = 1.17% (FCF TTM 38.9m / Enterprise Value 3.33b)
FCF Margin = 4.37% (FCF TTM 38.9m / Revenue TTM 890.6m)
Net Margin = 0.15% (Net Income TTM 1.35m / Revenue TTM 890.6m)
Gross Margin = 53.41% ((Revenue TTM 890.6m - Cost of Revenue TTM 414.9m) / Revenue TTM)
Gross Margin QoQ = 54.05% (prev 52.39%)
Tobins Q-Ratio = 4.52 (Enterprise Value 3.33b / Total Assets 736.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 237.6m)
Taxrate = 36.36% (769k / 2.12m)
NOPAT = 1.35m (EBIT 2.12m * (1 - 36.36%))
Current Ratio = 2.33 (Total Current Assets 357.7m / Total Current Liabilities 153.3m)
Debt / Equity = 0.63 (Debt 237.6m / totalStockholderEquity, last quarter 375.8m)
Debt / EBITDA = -0.94 (Net Debt -50.6m / EBITDA 54.0m)
Debt / FCF = -1.30 (Net Debt -50.6m / FCF TTM 38.9m)
Total Stockholder Equity = 368.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.19% (Net Income 1.35m / Total Assets 736.4m)
RoE = 0.37% (Net Income TTM 1.35m / Total Stockholder Equity 368.7m)
RoCE = 0.37% (EBIT 2.12m / Capital Employed (Equity 368.7m + L.T.Debt 205.8m))
RoIC = 0.24% (NOPAT 1.35m / Invested Capital 570.5m)
WACC = 10.55% (E(3.38b)/V(3.62b) * Re(11.29%) + D(237.6m)/V(3.62b) * Rd(0.0%) * (1-Tc(0.36)))
Discount Rate = 11.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 2.58%
[DCF] Terminal Value 66.69% ; FCFF base≈40.3m ; Y1≈37.7m ; Y5≈34.5m
[DCF] Fair Price = 4.20 (EV 399.3m - Net Debt -50.6m = Equity 449.9m / Shares 107.1m; r=10.55% [WACC]; 5y FCF grow -8.31% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.90 | Revenue CAGR: 13.66% | SUE: 1.59 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.12 | Chg30d=-3.36% | Revisions=-46% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.15 | Chg30d=-3.96% | Revisions=-44% | Analysts=10
EPS current Year (2026-12-31): EPS=0.47 | Chg30d=-2.28% | Revisions=-36% | GrowthEPS=+121.3% | GrowthRev=+12.4%
EPS next Year (2027-12-31): EPS=0.66 | Chg30d=-1.63% | Revisions=-25% | GrowthEPS=+40.7% | GrowthRev=+16.3%
[Analyst] Revisions Ratio: -47% (up=8, down=25)